|
|
|
|
|
|
|
03.06.26 - 13:03
|
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors (GlobeNewswire EN)
|
|
|
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced the appointment of Anna Greka, M.D., Ph.D., to its Board of Directors, effective June 15, 2026....
|
|
|
|
|
|
|
|
|
|
|
18.03.26 - 11:09
|
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire EN)
|
|
|
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today provided pipeline progress and business updates, including financial results for the fourth quarter and full year ended December 31, 2025. The Company reported favorable topline safety, tolerability and pharmacokinetics (PK) findings from the 7 mg dose cohort of OV329, its next generation GABA-aminotransferase (GABA-AT) inhibitor. Additionally the Company announced it will add complementary development programs for OV329, expanding into tuberous sclerosis complex (TSC) seizures and infantile spasms (IS) which is funded by a private placement financing expected to result in gross proceeds of $60.0 million, before deducting placement agent fees and offering expenses....
|
|
|
18.03.26 - 11:03
|
Ovid Therapeutics Announces Pricing of $60 Million Private Placement (GlobeNewswire EN)
|
|
|
NEW YORK, March 18, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of $60.0 million to the Company, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about March 19, 2026, subject to satisfaction of customary closing conditions....
|
|
|
|
|
|
|
02.12.25 - 13:03
|
Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer (GlobeNewswire EN)
|
|
|
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N., as Chief Medical Officer. Dr. Kaufmann joins Ovid's leadership team with responsibility for guiding clinical, medical, and regulatory strategy as the Company progresses a clinical pipeline of potential best- and first-in-class therapeutic candidates for conditions and symptoms driven by neuronal imbalance....
|
|
|
|
|
|
|
|
|
10.11.25 - 13:48
|
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer (Business Wire)
|
|
|
Physician-scientist brings more than two decades of R&D leadership experience in neuroscience, rare disease, and pain modulation at organizations including AbbVie, Ovid Therapeutics, Eisai Pharmaceuticals, and Takeda
CAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).
“Manoj is a recognized leader in neuroscience drug development, particularly in neurodegenerative diseases and epilepsy, with a proven record across the full spectrum of clinical development from early discovery through late-stage clinical development and regulatory approval,” said Kasper Roet, Ph.D., chief executive officer and co-founder of QurAlis. “His extensive experience combined with a deep commitment to patients will be a great additio...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
